학술논문
Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial
Document Type
Article
Author
Source
In The Lancet Infectious Diseases January 2024 24(1):25-35
Subject
Language
ISSN
1473-3099